Investor Presentation May 2016
|
|
- Bernard Preston
- 6 years ago
- Views:
Transcription
1 Investor Presentation May 2016
2 Forward Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forwardlooking statements as that term is defined in the Private Securities Litigation Reform Act of Any forward-looking statements contained herein are based on current expectations of Echo Therapeutics, Inc. ( Echo ), but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to Echo's ability to develop and obtain FDA approval of its CGM System; the availability of substantial additional equity capital to support Echo s research, development and product commercialization activities; and the success of Echo s business, research, development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in Echo s filings with the SEC, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2015, its quarterly report on Form 10-Q and its current reports on Form 8-K. Echo disclaims any intent or obligation to update these forward-looking statements. 2
3 Echo Company Overview Delivering Non-Invasive CGM Technology to Diabetics Echo Therapeutics (Nasdaq: ECTE) proven and proprietary technology continuously, and non-invasively measures glucose as effectively as leading invasive technologies Advancements in Echo CGM Technology Significant improvements made to accuracy, consistency, usability, and cost Echo s Addressable Market Echo is focused on helping the 29.1 million 1 in the U.S., 114 million 2 in China and 415 million 3 people worldwide with diabetes to manage their disease Currently only 8% of type 1 use CGM; the market is ripe for disruption Echo s Strategy Achieve CFDA approval, short term Establish relationships with FDA & EU Notified Body toward regulatory approval Continue development of non-invasive sensing technologies Utilize partnerships for commercialization for diabetes and other multi-billion dollar markets lnternational Diabetes Federation 3
4 Investment Highlights NASDAQ: ECTE Transforma)onal Technology Pla2orm Large and growing market opportunity Partnership opportuni)es Non-invasive, continuous glucose monitoring Proprietary skin preparation device and glucose sensor Clinically validated $10 billion global glucose monitoring market $1.5 billion CGM market opportunity 415 million people with diabetes worldwide Operational and strategic China partnership with MTIA Opportunities with other diabetes companies Broad IP por2olio Value crea)ng milestones Advanced clinical development 9 U.S, ~40 foreign, ~25 pending patents Cover glucose sensor and methods and skin preparation Core patents expire mid-to-late 2020s CFDA trial/approval Partnerships Re-designed, lower-cost products Establish manufacturing Wearables financing 114 patients and 8,844 data pairs Average MARD of 11.9% 93 studies completed in
5 Echo Therapeutics (NADSAQ: ECTE) Company Snapshot Ticker Nasdaq: ECTE Headquarters Iselin, NJ Employees 20 Common Stock Outstanding 1 Fully Diluted M 25.1 M Share Price 2 $1.60 Average Volume 2 ~36,000 Market Cap 2 ~$18.3 M 1 Does not include effect of January 29, 2016 sale of $5.145 million convertible notes and warrants. On a proforma basis, 14.5 M Common Stock outstanding and 31.6 fully diluted. 2 As May 7,
6 Echo s Proprietary System Non-invasive Continuous Glucose Monitoring Advancing our core technology for broad application in the diabetes market Skin Preparation Proprietary hand-held exfoliation device painlessly and precisely removes a portion of the dead layer of skin, or Stratum Corneum, for optimal glucose extraction Glucose Sensor & Bluetooth Transmitter Disposable sensor is applied directly to exfoliated area and continuously monitors glucose. Proprietary algorithm in reusable transmitter converts ISF measurements to blood glucose values and transmits data wirelessly Display and Software Architecture Custom applications display glucose trends and values on any standard platform. Published API makes it easy for developers to write Apps. Cloud server for storing glucose information and relaying data to remote apps 6
7 Technology Overview: Exfoliation & Glucose Detection Controlled removal of Stratum Corneum Stratum Corneum (outermost layer of dead skin) Epidermis (outermost layer of skin which serves as a barrier against the external environment ) Dermis (layer of skin above subcutaneous tissues/layer above where competitors insert needles) Glucose Oxidase enzyme Transmitter & Circuit Biosensor electrode Hydrogel (creates a seal over exfoliated area) Glucose diffusion into Gel 7
8 The Technology Works Numerous Clinical Trials Successfully Completed Clinical trials demonstrated that Echo s CGM non-invasively and continuously measures glucose in real-time in a way that accurately represents blood glucose levels Clinical Trials 7 studies, 114 patients, 8,844 data pairs IRB Study , Subject O-512 Site 1 Site 2 Site 3 Ref. BG Dexcom Accurate Average MARD* for clinical studies was 11.9% Safe Echo s non-invasive CGM is safe with no adverse events detected Recent Experience Promising data up to 72 hours Current (na) Time (hours) Blood Glucose (md/dl) *MARD: Mean Absolute Relative Difference; MARD is an evaluation of numerical accuracy represented as a percentage that indicates relative deviation of a sensor from a reference 8
9 Echo s Technology Summary of Clinical Trial Results Date Pa)ent Type # Pa)ents Data Pairs MARD (%) Jul 2008 T1/T Nov 2009 T1/T Sep 2011 Healthy Dec 2011 T1/T Apr 2012 CriCcal Care Key Takeaways: The Technology Works Today Achieved MARDs similar to or better than leading invasive CGMs The Technology Works in Multiple Patient Types Healthy Type 1 and Type 2 Diabetics Hospital Patients Jul 2012 CriCcal Care Nov 2013 CriCcal Care
10 Moving Our Technology Forward Adapting ICU technology for the consumer market Improving CGM accuracy, consistency, convenience and cost-effectiveness Exfoliator Sensor/Transmitter Display Improved Performance Effective & consistent exfoliations Updated and improved algorithm Consistent glucose tracking Simple mobile app to display data via BLE Published API for App developers Lower-Cost Less-expensive tips AA batteries Plastic enclosure Inexpensive disposable components Reusable transmitter Mobile platform replaces bulky, expensive monitor Consumer-Friendly Faster, 3-5 second exfoliation time Self-exfoliating design Ultra-thin, flexible housing Glucose data displayed on Android OS ios 10
11 Echo CGM Market Echo s Place in the Multi-Billion Dollar Diabetes Management Sector Accurate and reliable glucose measurements are the foundation for all diabetes related treatments and intervention Link CGM and pump for continuous care Echo CGM Echo CGM Correct types & doses of meds Provide complete picture of glucose trends and patterns Remote management of patient 11
12 How Echo s CGM Stacks Up Echo CGM System vs. Leading Competitors Dexcom G5 Target Markets Sensor Life Warm-up Time Calibrations Required MARD Medtronic Sof-Sensor Echo Sensor Bottom of sensor, no needle Out-patient diabetes Out-patient diabetes Out-patient diabetes 7 days (less accurate in first 4 days as seen in user manual) 6 days (less accurate in first few days) Up to 3 days (accurate immediately after warm-up time) 2 hours 2 hours 30 minutes Twice daily Four times a day Twice daily 9% 13.6% 11.9% historic (without improvements to exfoliation, sensor, or algorithm) Every 5 minutes Every 5 minutes Echo Every 5 minutes Reading Frequency Estimated Yearly Cost $5,985 $5,268 $2,500 Regulatory Status FDA Approved FDA Approved FDA meeting Q Company Market Cap $5.75B $107.08B $10.0 M 12
13 Potential Echo Wearables Spin-Out Exciting Opportunities in Non-Regulated Markets Optimizing Performance for Elite Athletes Simplifying Dieting for Healthy and Sustainable Weight-Loss Promoting Healthy Living and Preventative Care Remote Monitoring for Greater Independence and Peace of Mind 13
14 Potential Echo Wearables Spin-Out Creating Value for Echo Therapeutics Outline v Echo Therapeutics would own a majority interest in Echo Wearables spin-out creating value for Echo Therapeutics Mutually Beneficial Relationship v Feedback from potential partners mandating structural alignment v Echo Wearables would be able to raise independent capital Echo Therapeutics Proprietary noninvasive CGM technology Advances in technology Data generated from users Echo Wearables v Echo Wearables could design wearables focused product at no cost to Echo Therapeutics v Wearables market would not distract from diabetes product development 14
15 Business Development Update A Technology Company Focused on Partnerships Actively working with partners to manufacture and commercialize products in various segments Partnership Targets Diabetes related In 2015 we engaged 9 prospective partners Fields include: Drug, associated devices, academic institutions, diabetes equipment manufacturers, food companies, information providers, data amalgamators and hubs Wearables related In 2015 we engaged 87 prospective partners Fields include: Traditional Fitness devices, beverage companies, professional and division I sports teams and athletes, Olympic committees, lifestyle information services, weight-loss programs, nutritionists and big data companies 15
16 Echo s Partnership With MTIA Strong Manufacturing, Marketing, and Distribution Partner in China The goal of Echo s partnership with MTIA is to gain CFDA approval for Echo s CGM system and develop the product based on commercial costs Current Status: All documents have been transferred and translated Tech transfer complete In house testing in progress with domestically produced components Primary investigator on board Upcoming Events: Echo team to visit MTIA facilities in order to assist and confirm progress (Q1 2016) Commencement of CFDA clinical trials (Q3 2016) Echo Responsibilities Implement improvements to existing Gen 2 system Create and transfer all technical information Supportive testing of MTIA manufactured sensors Design and transfer API for China apps (IP protected) Consult with MTIA on next-gen sensor Implement standards for China s evolving regulatory requirements MTIA Responsibilities Receive and translate all historic documents Engage manufacturers and establish all requirements for manufacturing In house testing of domestically made sensors (confirmed by Echo) Integrate translated documents into Chinese based quality system Create regulator strategy and interface with CFDA Create protocol based on CFDA feedback Establish principle investigator and screen potential clinical sites 16
17 Echo s Intellectual Property Broad Intellectual Property Estate 9 U.S. patents, ~70 foreign patents, ~25 patents pending worldwide Most issued core patents expire mid-to-late 2020s Method and Device Patents cover a broad range of applications Glucose sensor and methods hydrogel formulation glucose measurement algorithm Diffusion and measurement glucose through prepared site Skin Preparation Electronic feedback control mechanism for precise and controlled removal of barrier Transdermal drug delivery Minimum of 10 new patent applications based on NextGen System 17
18 2016 Milestones Q1 2016: Q2 2016: Echo team visits China to support and confirm MTIA process Internal clinical testing of new sensor and hydrogel Q2 2016: Working prototype NextGen system Q3 2016: Begin CFDA trial Q3 2016: Q3 2016: Q4 2016: Q4 2016: Complete CFDA Trial and report preliminary data Initial clinical testing for NextGen system Initial meeting with FDA File for CFDA approval. 18
19 Thank You
Cowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationBetter Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation November 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.
More informationBetter Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation December 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.
More informationconfidently live life with ease Management Presentation
confidently live life with ease Management Presentation 1 Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationDexcom Current and Future Technology Innovations. Jorge Valdes Chief Technical Officer
Dexcom Current and Future Technology Innovations 2015 Jorge Valdes Chief Technical Officer G5 App Sensor (Same as G4) Indicated for adults and children down to Age 2 years Tiny insertion needle (26Ga)
More informationCOMPANY OVERVIEW. April 26, 2018
COMPANY OVERVIEW April 26, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationCOMPANY OVERVIEW. July 30, 2018
COMPANY OVERVIEW July 30, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationNon-Invasive Glucose Monitoring. Kevin Walls April 12, :30 PM-7:30 PM.
Non-Invasive Glucose Monitoring Kevin Walls April 12, 2018 6:30 PM-7:30 PM. Technology is evolving Technology is evolving at such a rapid rate it s hard to keep up. Imagine living a healthier life without
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationCanaccord Growth Conference August confidently live life with ease
Canaccord Growth Conference August 2018 confidently live life with ease Forward-Looking Statements This presentation contains forward-looking statements that are not purely historical regarding Senseonics
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationTandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile
Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationDIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson
DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson March 3 rd, 2018 Who is this guy? Accelerating Progress 1 Oh that guy! Accelerating Progress 2 STATE OF T1D CARE
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationCOMPANY OVERVIEW. October 12, 2017
COMPANY OVERVIEW October 12, 2017 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationForward-looking Statements
September 2011 Forward-looking Statements Information contained in this presentation may contain forward-looking statements, including, but not limited to: the expectation that Easy Check and GlucoChip
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationLabStyle Innovations Corp. (OTCQB:DRIO)
LabStyle Innovations Corp. (OTCQB:DRIO) End to End Smart Solutions for Diabetes in a Mobile Age Disclaimer Regarding Forward-Looking Statements This presentation of LabStyle Innovations Corp. (the Company
More information(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health. December 2018
(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health December 2018 Safe Harbor Statement All statements in this presentation that are not based on historical fact are forward looking statements.
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationSAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationAfter simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up.
New Medical Device Company Addresses Two Very High Demand Markets with its Proprietary Products. Trader Tracks likes this company as they provide reasonably priced equipment and testing while medical costs
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationMonitoring of Blood Glucose Level
University of Zagreb Faculty of Electrical Engineering and Computing Biomedical instrumentation Monitoring of Blood Glucose Level Biomedical instrumentation 1/17 Outline Introduction Principles of Blood
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationDexcom: CGM technology, IoT connectivity, and the drive to insight delivery in diabetes care
Data @ Dexcom: CGM technology, IoT connectivity, and the drive to insight delivery in diabetes care Nate Heintzman, PhD Sr. Manager, Data Partnerships 20161130 MILLIONS 700 Diabetes is a global crisis
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationGrowth Conference. October 19, May 2013
Dawson Corporate James Securities Presentation 3rd Annual Small Cap Growth Conference October 19, 2017 May 2013 Safe Harbor This document contains forward-looking statements within the meaning of the "safe
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More informationN A S D A Q : E V F M
N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationFor personal use only
Nuheara Ltd TechKnow May 2016 Justin Miller CEO & Co-founder Presentation Justin Miller CEO & Co-founder Melbourne 23 March 2017 CORPORATE SUMMARY 2 Company Snapshot Successfully listed on ASX March 2,
More informationNovember 2016 NASDAQ: ATRS
November 2016 NASDAQ: ATRS Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCOURSE LISTING. Courses Listed. Training for Database & Technology with Administration in SAP Hybris Commerce. 17 August 2018 (04:00 BST) Einsteiger
Training for Database & Technology with Administration in SAP Hybris Commerce Courses Listed Einsteiger HY100 - SAP Hybris Commerce Product Overview HY100E - SAP Hybris Commerce Essentials Online Grundlagen
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCOURSE LISTING. Courses Listed. Training for Cloud with SAP Hybris in Commerce for System Administrators. 26 September 2018 (22:37 BST) Einsteiger
Training for Cloud with SAP Hybris in Commerce for System Administrators Courses Listed Einsteiger HY100 - SAP Hybris Commerce Product Overview HY100E - SAP Hybris Commerce Essentials Online Grundlagen
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More information10:20 AM March 5, B 100% 235 u. 124 mg/dl 3 HRS INSULIN ON BOARD:
DEXCOM G5 MOBILE CGM COMPATIBLE B 100% 235 u INSULIN ON BOARD: OPTIONS 10:20 AM March 5, 2017 400 350 300 250 200 150 100 50 1.1 u 1:09 hrs BOLUS 124 mg/dl 3 HRS The pump that gets updated, not outdated.
More information22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationPeople with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT
Position Statement People with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT Diabetes Australia believes that people with diabetes should have choice and access
More informationYour track to health!... A Truly Non-Invasive Glucose Monitor for Self Use
Your track to health!... A Truly Non-Invasive Glucose Monitor for Self Use 1 Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationNeovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum
Neovasc Inc. Alexei Marko, CEO January 2012 OneMedForum 2 Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More information概美科技. GuideMia Technologies, LLC Sept
概美科技 info@guidemia.com GuideMia Technologies, LLC Sept 2017 +1 714 391 2739 Offering worldwide dentists and dental labs image guided implant and digital orthodontics solutions and services that change
More informationAlertness and Sleep Health Management Research & Technology. Strategic Opportunity Overview
Alertness and Sleep Health Management Research & Technology Strategic Opportunity Overview (V2, updated 11/9/18) Myron Kassaraba, Managing Director MJK Partners, LLC myron@mjkpartners.com Tel: 617-448-9558
More informationLED Medical Diagnostics Inc. TSXV: LMD / OTCQB:LEDIF
LED Medical Diagnostics Inc. TSXV: LMD / OTCQB:LEDIF WHAT WE DO LED Medical Diagnostics Inc. provides software and imaging device solutions to Dentists, Dental Support Organizations (DSOs) & the US Military
More informationSMARTPILOT FOR YPSOMATE: TRANSFORMING A PROVEN AUTOINJECTOR INTO A FULLY CONNECTED DEVICE
SMARTPILOT FOR YPSOMATE: TRANSFORMING A PROVEN AUTOINJECTOR INTO A FULLY CONNECTED DEVICE In this article, Orfeo Niedermann, Business Development Director, Ypsomed Delivery Systems, provides insights into
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationCALIPSO Project. an innovative approach to insulin therapy management
CALIPSO Project an innovative approach to insulin therapy management Preface Our project Preliminary business plan Project Team Calipso Project 2015 Why it should be so hard for diabetics to manage their
More information- Non-invasive - Mobile; collect data continuously at anywhere and any time - Used outside clinical setting
Background Advances in medical technologies are increasing remote patient monitoring programs. These technologies enable healthcare professionals to monitor the health status of patients outside clinical
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationTABLE OF CONTENTS. HLC102A - Continuous Glucose Monitoring (CGM): Technologies and Global Markets
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1 STUDY GOALS AND OBJECTIVES 1 REASONS FOR DOING THIS STUDY 1 CONTRIBUTIONS TO THE STUDY AND INTENDED AUDIENCE 1 SCOPE AND FORMAT 1 METHODOLOGY AND INFORMATION
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationPROJECT PERIODIC REPORT
PROJECT PERIODIC REPORT Project acronym: Project full title: Grant agreement no: CuPiD Closed-loop system for personalized and at-home rehabilitation of people with Parkinson's Disease ICT 288516 Project
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationPress Release. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D
Press Release RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D Top-line results are expected in the third quarter of 2017 The randomized, double-blind, placebo-controlled
More information